scholarly journals EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma

2018 ◽  
Vol 13 (6) ◽  
pp. e93-e95 ◽  
Author(s):  
Liang Zeng ◽  
Yongchang Zhang ◽  
Nong Yang
Keyword(s):  
Lung Adenocarcinoma ◽  
Acquired Resistance ◽  
Resistance Mechanism

scholarly journals Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report

2021 ◽  
Vol 11 ◽  
Author(s):  
Xia Wang ◽  
Weiwei Peng ◽  
Zhimin Zeng ◽  
Jing Cai ◽  
Anwen Liu
Keyword(s):  
Case Report ◽  
Lung Adenocarcinoma ◽  
Kinase Inhibitors ◽  
Fusion Gene ◽  
Acquired Resistance ◽  
Resistance Mechanism ◽  
Growth Factor Receptor ◽  
Progression Free Survival ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
Nsclc Patients

BackgroundEpidermal growth factor receptor (EGFR) fusions are rare genomic events in non-small-cell lung cancer (NSCLC). Clinical support and evidence to guide management are absent for NSCLC patients harboring EGFR fusion.Case PresentationIn this case report, we describe a 69-year-old female who received right lobectomy and was diagnosed with pathological stage IIIA lung adenocarcinoma harboring EGFR L858R. Twenty months later he had recurrent disease in the liver, lung, and bone, and was treated with icotinib. A novel vesicular overexpressed in cancer pro-survival protein 1 (VOPP1)-EGFR fusion gene coexistent with T790M were identified by next-generation sequencing using pericardial effusion and blood samples after icotinib treatment, which led to progression after icotinib six months and suggested a potential resistance mechanism. Subsequently, the patient was switched to osimertinib treatment, which resulted in a progression-free survival interval of more than 11 months.ConclusionsThe present results suggested that acquired VOPP1-EGFR fusion gene with T790M potentially serve an additional resistance mechanism to first-generation EGFR tyrosine kinase inhibitors in EGFR-mutated NSCLC. And the present case increases the evidence supporting use of osimertinib for treatment of NSCLC patients harboring EGFR fusion.

Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma

2015 ◽  
Vol 14 (10) ◽  
pp. 2238-2248 ◽  
Author(s):  
Chan Woo Kang ◽  
Kang Won Jang ◽  
Jinyoung Sohn ◽  
Sung-Moo Kim ◽  
Kyoung-Ho Pyo ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Lung Adenocarcinoma ◽  
Acquired Resistance ◽  
Resistance Mechanism

Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma

Lung Cancer ◽  
2016 ◽  
Vol 92 ◽  
pp. 15-18 ◽  
Author(s):  
Charline Caumont ◽  
Rémi Veillon ◽  
Audrey Gros ◽  
Elodie Laharanne ◽  
Hugues Bégueret ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Acquired Resistance ◽  
Resistance Mechanism
Sign in / Sign up

Export Citation Format

Share Document